Segueix
Bruce Dorsey
Bruce Dorsey
Retired Arbutus Biopharma, Inc.
No hi ha cap correu electrònic verificat
Títol
Citada per
Citada per
Any
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.
JP Vacca, BD Dorsey, WA Schleif, RB Levin, SL McDaniel, PL Darke, ...
Proceedings of the national academy of sciences 91 (9), 4096-4100, 1994
6951994
L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor
BD Dorsey, RB Levin, SL McDaniel, JP Vacca, JP Guare, PL Darke, ...
Journal of medicinal chemistry 37 (21), 3443-3451, 1994
5451994
Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery
AK Ghose, T Herbertz, RL Hudkins, BD Dorsey, JP Mallamo
ACS chemical neuroscience 3 (1), 50-68, 2012
3942012
A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site
MK Holloway, JM Wai, TA Halgren, PMD Fitzgerald, JP Vacca, BD Dorsey, ...
Journal of medicinal chemistry 38 (2), 305-317, 1995
3091995
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer
BD Dorsey, M Iqbal, S Chatterjee, E Menta, R Bernardini, A Bernareggi, ...
Journal of medicinal chemistry 51 (4), 1068-1072, 2008
1782008
HIV protease inhibitors useful for the treatment of AIDS
JP Vacca, BD Dorsey, JP Guare, MK Holloway, RW Hungate, RB Levin
US Patent 5,413,999, 1995
1641995
Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells
W Wan, MS Albom, L Lu, MR Quail, NC Becknell, LR Weinberg, ...
Blood 107 (4), 1617-1623, 2006
1572006
Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines
CS Burgey, KA Robinson, TA Lyle, PEJ Sanderson, SD Lewis, BJ Lucas, ...
Journal of medicinal chemistry 46 (4), 461-473, 2003
1282003
Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates
PEJ Sanderson, TA Lyle, KJ Cutrona, DL Dyer, BD Dorsey, ...
Journal of medicinal chemistry 41 (23), 4466-4474, 1998
1221998
Anti-cancer agents and uses thereof
M Kelly, Y Lee, B Liu, T Fujimoto, J Freundlich, BD Dorsey, GA Flynn, ...
US Patent App. 11/819,494, 2008
1172008
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis
KL Stump, LD Lu, P Dobrzanski, C Serdikoff, DE Gingrich, BJ Dugan, ...
Arthritis research & therapy 13, 1-15, 2011
1052011
Identification of 1-(3-(6, 7-dimethoxyquinazolin-4-yloxy) phenyl)-3-(5-(1, 1, 1-trifluoro-2-methylpropan-2-yl) isoxazol-3-yl) urea hydrochloride (CEP-32496), a highly potent …
MW Rowbottom, R Faraoni, Q Chao, BT Campbell, AG Lai, E Setti, ...
Journal of medicinal chemistry 55 (3), 1082-1105, 2012
952012
Discovery of clinical candidate CEP-37440, a selective inhibitor of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK)
GR Ott, M Cheng, KS Learn, J Wagner, DE Gingrich, JG Lisko, M Curry, ...
Journal of medicinal chemistry 59 (16), 7478-7496, 2016
832016
Benzodiazepines as potent and selective bradykinin B1 antagonists
MR Wood, JJ Kim, W Han, BD Dorsey, CF Homnick, RM DiPardo, ...
Journal of medicinal chemistry 46 (10), 1803-1806, 2003
832003
Anti-cancer agents and uses thereof
M Kelly, BD Dorsey, GA Flynn
US Patent 7,504,401, 2009
822009
Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1
JJ Park, EP Thi, VH Carpio, Y Bi, AG Cole, BD Dorsey, K Fan, T Harasym, ...
Nature Communications 12 (1), 1222, 2021
792021
A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-a]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779
BJ Dugan, DE Gingrich, EF Mesaros, KL Milkiewicz, MA Curry, AL Zulli, ...
Journal of medicinal chemistry 55 (11), 5243-5254, 2012
792012
Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2
LD Lu, KL Stump, NH Wallace, P Dobrzanski, C Serdikoff, DE Gingrich, ...
The Journal of Immunology 187 (7), 3840-3853, 2011
762011
CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers
M Cheng, MR Quail, DE Gingrich, GR Ott, L Lu, W Wan, MS Albom, ...
Molecular cancer therapeutics 11 (3), 670-679, 2012
742012
L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor
PEJ Sanderson, KJ Cutrona, BD Dorsey, DL Dyer, CM McDonough, ...
Bioorganic & medicinal chemistry letters 8 (7), 817-822, 1998
681998
En aquests moments el sistema no pot dur a terme l'operació. Torneu-ho a provar més tard.
Articles 1–20